Trials / Completed
CompletedNCT00633269
Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours
Open, Non-Randomized, Single Centre Phase I Study to Assess the Metabolism, Excretion and Pharmacokinetics of a Single Oral 100 mg Dose of [14C]-AZD2281 (KU-0059436) in Patients With Advanced or Metastatic Solid Tumours Refractory to Standard Treatments
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open, non-randomized, radiolabelled, single centre study designed to characterize the metabolism, excretion and pharmacokinetics of a single oral dose of 100 mg \[14C\]-radiolabelled AZD2281 (KU-0059436) in patients with advanced or metastatic solid tumours.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD2281 | 100mg Oral Dose |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2008-03-12
- Last updated
- 2009-01-14
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00633269. Inclusion in this directory is not an endorsement.